https://orcid.org/0000-0001-8980-2410
Current Duke Appointments & Affiliations
Instructor in the Department of Medicine
·
2020 - Present
Medicine, Medical Oncology,
Medicine
Member of the Duke Cancer Institute
·
2022 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Scholarly Works
Clinical and genomic determinants of extraordinary response and resistance to androgen receptor pathway inhibitors in men with metastatic androgen pathway modulator sensitive (APMS) prostate cancer.
Journal article Prostate Cancer Prostatic Dis · August 5, 2026 BACKGROUND: Identifying clinical and genomic predictors of response to androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPI) for metastatic androgen pathway modulator sensitive (APMS) prostate cancer is essential for improving ... Full text Link to item CiteEnfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer.
Journal article N Engl J Med · July 23, 2026 BACKGROUND: Neoadjuvant cisplatin-based chemotherapy is a standard therapy for muscle-invasive bladder cancer. The efficacy and safety of neoadjuvant and adjuvant (perioperative) enfortumab vedotin-pembrolizumab as compared with neoadjuvant cisplatin-based ... Full text Link to item CiteOutcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study.
Journal article Eur Urol · July 2026 Full text Link to item CiteRecent Grants
TulmiSTAR-01: A two-part, Phase I dose escalation and expansion followed by a randomized, open-label multicenter, Phase II study to assess the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide) vs standard
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2025 - 2031A Phase 1 Open-Label, Multicenter Study of JANX014 in Participants with Prostate Cancer
Clinical TrialPrincipal Investigator · Awarded by Janux Therapeutics, Inc. · 2026 - 2031A Phase 1 Dose-Escalation and Expansion Study Evaluating the Safety, Efficacy, and Pharmacokinetics of EVOLVE104 in Subjects with Advanced Urothelial and Squamous Cell Carcinomas
Clinical TrialPrincipal Investigator · Awarded by EvolveImmune United, Inc. · 2026 - 2031View All Grants
Education
New York Institute of Technology, College of Osteopathic Medicine ·
2001
D.O.